
News Releases

News Releases

2008

Jul 2, 2008	Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Jun 25, 2008	Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Jun 10, 2008	Revision of Performance Forecast
Jun 2, 2008	Santen Files Manufacturing and Marketing Approval for Corneal and Conjunctival Epithelial Disorder Treatment
Jun 2, 2008	Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions
May 23, 2008	Santen to Issue Stock Acquisition Rights to the Corporate Officers for the Purpose of Granting Stock Options
May 23, 2008	Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options
May 20, 2008	Notice on Board of Directors, Corporate Auditors and Corporate Officers
May 8, 2008	Santen Announces Financial Results for the Year ended March 31, 2008
May 7, 2008	Santen Oy Receives Marketing Authorization for its Glaucoma and Ocular Hypertension Treatment, TAFLOTAN® in Denmark
Mar 26, 2008	Notice Regarding the Completion of Purchase of the Company's Own Shares in the Market
Mar 6, 2008	Notice Regarding the Purchase of the Company's Own Shares in the Market
Feb 25, 2008	Santen to Lift Condition for Approval of PAPILOCK Mini Ophthalmic Solution 0.1%
Jan 30, 2008	Santen to Purchase Own Shares
Jan 30, 2008	Santen Announces Financial Result for the Third Quarter ended December 31, 2007 Appendix
Jan 11, 2008	Santen to Launch Nutritional Supplement Sante Lutax


	Download Adobe® Reader® to view PDF files.

2008